Latest Cancer News

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer (11-9-2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more [...]


FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (11-6-2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to [...]


Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer (11-1-2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers [...]


Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer (10-30-2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal [...]


Radius Health Receives FDA Fast Track Designation for Elacestrant (10-26-2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. Fast Track designation is a process designed to facilitate the development and expedite the [...]


Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer (10-23-2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior to standard chemotherapy and significantly improves survival. Lung cancer remains the leading cause [...]


Flu Shot 101 – What You Need to Know (10-19-2017)

Flu season is here again, and besides a fever and runny nose, it can bring about the longtime controversy surrounding vaccines. In order to protect more human lives this year and to clarify some of the most common misconceptions surrounding the flu vaccine, the team at ConsumerSafety.org met with Dr. [...]


FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (10-18-2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” said [...]


Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer (10-17-2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit [...]


Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (10-16-2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, [...]


Immunotherapy Active Against Triple-Negative Breast Cancer (10-12-2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that [...]


LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10-10-2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA [...]


« Previous PageNext Page »